Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-RISEDRONATE | 35MG | TABLET | Resolved | 2018-10-19 | 2018-12-21 | 64981 |
| APO-RISEDRONATE | 150MG | TABLET | Resolved | 2017-08-31 | 2017-10-20 | 20704 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2017-06-28 | 2017-12-01 | 14216 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2017-06-28 | 2017-11-30 | 14219 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2017-07-26 | 2017-11-29 | 17319 |
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2017-08-23 | 2017-11-29 | 20122 |
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2017-08-31 | 2017-11-30 | 20707 |
| APO-RISPERIDONE | 3.0MG | TABLET | Resolved | 2021-05-14 | 2021-06-21 | 139422 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2021-05-14 | 2021-06-21 | 139425 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2021-06-04 | 2021-06-21 | 140428 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2021-07-16 | 2021-08-31 | 142687 |
| APO-RISPERIDONE | 4.0MG | TABLET | Resolved | 2019-10-09 | 2019-10-29 | 95882 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2019-12-12 | 2020-03-27 | 101097 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2020-01-22 | 2020-03-27 | 103920 |
| APO-RISPERIDONE | 3.0MG | TABLET | Resolved | 2020-06-10 | 2020-07-13 | 117407 |
| APO-RISPERIDONE | 0.50MG | TABLET | Resolved | 2025-01-30 | 2025-02-21 | 249089 |
| APO-RISPERIDONE | 0.25MG | TABLET | Resolved | 2020-08-06 | 2020-11-09 | 121913 |
| APO-RISPERIDONE | 1.0MG | TABLET | Resolved | 2020-10-14 | 2020-11-09 | 126314 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2020-10-14 | 2020-11-09 | 126317 |
| APO-RISPERIDONE | 2.0MG | TABLET | Resolved | 2021-02-19 | 2021-04-05 | 134442 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-BISACODYL | 5MG | TABLET (DELAYED-RELEASE) | Discontinued | 2018-09-07 | 2018-09-15 | 60288 |
| APO-BOSENTAN | 62.5MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71339 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71342 |
| APO-BOSENTAN | 125.0MG | TABLET | Discontinued | 2018-09-07 | 2018-10-31 | 60291 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2018-09-07 | 2018-12-28 | 60301 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | Discontinued | 2020-11-16 | 2020-11-16 | 128438 |
| APO-BRIMONIDINE | 0.2% | SOLUTION | To be discontinued | 2018-09-07 | 2018-09-07 | 60294 |
| APO-BROMAZEPAM - TAB 1.5MG | 1.5MG | TABLET | To be discontinued | 2018-09-07 | 2018-09-07 | 60304 |
| APO-BROMAZEPAM - TAB 3MG | 3MG | TABLET | Discontinued | 2018-09-07 | 2019-06-12 | 60307 |
| APO-BROMAZEPAM - TAB 6MG | 6MG | TABLET | Discontinued | 2018-09-07 | 2018-10-19 | 60310 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60313 |
| APO-CANDESARTAN | 16MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60316 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60325 |
| APO-CANDESARTAN | 8MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60322 |
| APO-CANDESARTAN | 4MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60319 |
| APO-CANDESARTAN | 32MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60328 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60331 |
| APO-CANDESARTAN/HCTZ | 25MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-05-03 | 41011 |
| APO-CANDESARTAN/HCTZ | 12.5MG 32MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41020 |
| APO-CANDESARTAN/HCTZ | 12.5MG 16.0MG | TABLET | Discontinued | 2018-02-26 | 2018-02-26 | 41047 |